| Size | 20 µg, 100 µg |
| Estimated Lead Time | 1-2 weeks |
| Species | Human |
| Specificity | Does not react with rat. Other species not tested. |
| Host Species | Mouse |
| Accession Number | P55317 |
| Gene Id | 3169 |
| Gene Symbols | FOXA1, HNF3A, TCF3A |
| Protein Name / Synonyms | Hepatocyte nuclear factor 3-alpha (HNF-3-alpha) (HNF-3A) (Forkhead box protein A1) (Transcription factor 3A) (TCF-3A) |
| Immunogen | A human partial recombinant protein corresponding to amino acids 372-472 was used as the immunogen for this FOXA1 antibody. |
| Isotype | Kappa, IgG1 |
| Purity | Protein G affinity chromatography |
| Concentration (lot specific) | 0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide |
| Recommended Applications | FACS: 0.5-1ug/10^6 cells IF: 1-2ug/ml Western Blotting: 0.5-1ug/ml IHC (FFPE): 1-2ug/ml for 30 min at RT |
| Domain / Region / Terminus | Nuclear |
| Shipping Type | Blue ice |
| Storage | ≤-20°C |
FOXA1 in breast cancer is highly correlated with ERalpha+, GATA3+, and PR+ protein expression as well as endocrine signaling. FOXA1 acts as a pioneer factor for ERa in ERalpha+ breast cancer, and its expression might identify ERalpha+ cancers that undergo rapid reprogramming of ERa signaling that is associated with poor outcomes and treatment resistance. Conversely, in ERalpha− breast cancer FOXA1 is highly correlated with low-grade morphology and improved disease free survival. FOXA1 is a downstream target of GATA3 in the mammary gland. Expression in ERalpha− cancers may identify a subset of tumors that is responsive to other endocrine therapies such as androgen receptor antagonist treatment. [Wiki]
Your cart is empty.
Anti-FOXA1 Antibody
Anti-FOXA1 Antibody